pharmaphorum

DECEMBER 23, 2021

After EGFR therapy fails, platinum-based chemo has limited efficacy, generally preventing disease progression or death for between four and six months. Daiichi Sankyo has now started a phase 2 trial – called HERTHENA-Lung01 – in 420 patients with EGFR-mutated NSCLC previously treated with at least one EGFR inhibitor and platinum-based chemo.

Drugs 70

Drugs Antibody Clinical Trials Clinical Trials 70

The Pharma Data

OCTOBER 21, 2020

22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer. Among adults with ALL, 10% to 20% die during chemo, according to Dr. Dieter Hoelzer, of the University of Frankfurt, in Germany. The chemo-free approach could shorten that. © 2020 HealthDay.

Drugs 52

Drugs Genetics Trials Research 52

The Pharma Data

OCTOBER 21, 2020

22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer. Among adults with ALL, 10% to 20% die during chemo, according to Dr. Dieter Hoelzer, of the University of Frankfurt, in Germany. The chemo-free approach could shorten that. © 2020 HealthDay.

Drugs 52

Drugs Genetics Trials Research 52

pharmaphorum

APRIL 27, 2022

The top-line results showed that Enhertu (trastuzumab deruxtecan) achieved a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) when compared to physicians’ choice of chemo.

Sales 57

Sales Drugs Antibody Licensing 57

pharmaphorum

OCTOBER 29, 2021

Gilead is sponsoring the new study to see if adding Trodelvy can be an alternative chemo when added to Keytruda in the first-line treatment of advanced TNBC, in the hope of moving the ADC up the treatment pathway. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on.

Trials 52

Trials Sales FDA Approval Production 52